Test Price
2,800 AED✅ Home Collection Available
SLC9A3R1 Genetic Test (Nephrolithiasis/Osteoporosis, Hypophosphatemic Type 2) in UAE – 2,800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified NGS processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This test uses Next-Generation Sequencing to detect pathogenic variants in the SLC9A3R1 gene, associated with autosomal recessive nephrolithiasis/osteoporosis, hypophosphatemic type 2. Recommended by a multidisciplinary team including nephrologists, endocrinologists, and clinical geneticists, it enables early diagnosis and targeted management.
| Feature | Our Test (NGS Full Gene) | Closest Alternative (Single‑Exon Sanger) |
|---|---|---|
| Precision / Sensitivity | 99.9% diagnostic sensitivity | ~85% (misses deep intronic/CNV) |
| Methodology | Next‑Generation Sequencing (Illumina NovaSeq) + ACMG variant interpretation | Capillary sequencing of selected exons; limited scope |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Price (AED) | 2,800 | ~2,500 (may require reflex to full gene, extra cost) |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I strongly advise that the SLC9A3R1 test result be interpreted in conjunction with serum phosphate, renal ultrasound, and bone densitometry. A positive variant confirms the diagnosis and enables cascade family screening, while a negative result does not exclude other hereditary or acquired causes. Please maintain your prescribed medications and consult your treating specialist for a personalized management plan.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Medication Advisory
Do not discontinue prescribed medications without consulting your doctor. This genetic test is a diagnostic aid and does not replace clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals under 18 years without legal guardian consent (per UAE PDPL and Federal Law No. 2 of 2019); inability to provide informed consent for genetic testing; recent blood transfusion (within 2 weeks) that may compromise DNA purity.
- Red Flags – Seek Immediate Medical Help: Sudden severe bone pain or unexplained fracture; acute renal colic with fever or hematuria; signs of acute kidney injury (oliguria, confusion). Do not rely solely on test results; go to the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What does the SLC9A3R1 genetic test detect?
The SLC9A3R1 genetic test uses Next-Generation Sequencing to detect mutations in the SLC9A3R1 gene, which are linked to hereditary kidney stones, osteoporosis, and hypophosphatemic type 2. Results are typically available in 3–4 weeks.
2. How should I prepare for the test?
No fasting is required. You need to provide a blood sample (EDTA tube) or previously extracted DNA. A mandatory genetic counseling session will document your family pedigree to optimize result interpretation.
3. Is the SLC9A3R1 test covered by UAE health insurance?
Yes, we verify direct billing with major UAE insurers. Contact our WhatsApp at +971 54 548 8731 for pre-authorization and instant coverage confirmation.
UAE Regulatory & Data Privacy Adherence
All genetic testing at DNA Labs UAE is conducted in full compliance with: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information is encrypted, stored securely, and never shared without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | SLC9A3R1 Genetic Test (Nephrolithiasis/Osteoporosis, Hypophosphatemic Type 2) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood or extracted DNA (EDTA tube) |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeq) with ACMG variant interpretation |
| ICD-10-CM Code | E83.39 |
| LOINC Code | 47527-7 |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians